Medical treatment of pediatric urolithiasis by Alon, Uri S.
EDUCATIONAL FEATURE
Medical treatment of pediatric urolithiasis
Uri S. Alon
Received: 1 November 2007 /Revised: 13 December 2007 /Accepted: 13 December 2007 /Published online: 14 February 2008
# IPNA 2008
Abstract In recent years the incidence of pediatric stone
disease has increased several fold, mostly due to hyper-
calciuria and hypocitraturia. The goal of medical treatment
is to protect the patient from formation of new stones and
expansion of existing ones. The non-pharmacological
means to address stone disease include high fluid intake and,
frequently, modification of nutritional habits. The pharmaco-
logical treatment is based on the chemical composition of the
stone and the biochemical abnormalities causing its formation;
hence, chemical analysis of the stone, urine and blood is of
paramount importance and should be done when the first stone
is detected. This review discusses the current options of
medical treatment of pediatric urolithiasis.
Keywords Hypercalciuria.Hypocitraturia.Oxaluria.
Potassium.Sodium.Urolithiasis
Introduction
Most recent studies report that the incidence of kidney and
ureteral stones has increased significantly in both adults and
children [1–3]. Others, however, report no change in
incidence [4]. Most stones in children are composed of
calcium oxalate and calcium phosphate, or a combination
of the two. The two more common pathophysiologic
mechanisms of these stones are idiopathic hypercalciuria
and hypocitraturia [3, 5]. Assuming that the genetic pool of
patients predisposed to these conditions has not changed
dramatically, one can speculate that the main reason for the
rise in incidence is mostly due to environmental factors.
The latter possibly include changes in nutritional habits,
regional climate changes (http://en.wikipedia.org/wiki/
Global_warming) and decreased fluid intake.
Unfortunately, chemolysis is effective only in a small
fraction of specific stones, like alkali therapy for uric acid
stones and when combined with thiols (see below) for
cystine stones, and urine acidification for struvite stones.
Furthermore, in most cases, chemolysis is used for local
irrigation, although, on occasions, it can be used as
systemic therapy [6]. Therefore, in almost all cases,
removal of existing stones remains in the domain of the
urologist. The medical treatment of urolithiasis is aimed at
protecting the patient from further growth of existing stones
and development of new stones, thus decreasing morbidity
and the need for surgical intervention. Hence, under these
circumstances, medical treatment, in practicality, means
prevention. To achieve this goal it is important for one to
obtain stone analysis, if feasible, and urine chemistry
analysis as early as possible (Table 1). In essence, this
challenging treatment has two main avenues which operate
in concert: the non-pharmacological one and the pharma-
cological one (Table 2). This review addresses these two
aspects of the medical treatment of the more common stone
disorders in childhood and adolescence.
Non-pharmacological intervention
Fluids
The universal and probably most important component of
the treatment of all kinds of kidney stones is increased urine
volume, thereby decreasing solute concentration and,
consequently, supersaturation [7]. As shown by Miller and
Stapleton [8] children with urolithiasis tend to have a lower
24 hour urine volume than do controls. Lande et al. [9],
studying 32 children with urolithiasis, showed that urine
Pediatr Nephrol (2009) 24:2129–2135
DOI 10.1007/s00467-007-0740-7
U. S. Alon (*)
Bone and Mineral Disorders Clinic, Pediatric Nephrology,
Children’s Mercy Hospital and Clinics,
University of Missouri at Kansas City,
2401 Gillham Road,
Kansas City, MO 64108, USA
e-mail: ualon@cmh.eduflow of >1 ml/kg per hour, almost eliminated the risk of
supersaturation for calcium oxalate, calcium phosphate and
uric acid, thus protecting from the formation of the
corresponding kidney stones. In a child weighing 40 kg
this translates to 960 ml urine/24 h. In patients with
cystinuria the required urine flow may be even higher (see
below), and, in other cases, such as primary xanthinuria,
high fluid intake is the only therapy available. In most
patients, for them to achieve the desired urine output, an
increase in oral fluid intake is required. Although no studies
were done in children, in a large scale epidemiologic study
in women, Curhan et al. [7] found that coffee, tea and
alcoholic beverages decreased the risk of stone formation,
whereas grapefruit juice increased it. In a previous study in
men, the same group showed an increased risk for stone
formation associated with grapefruit and apple juice [10].
The reason for the association of these two beverages with
increased stone risk is unknown. Milk, other fruit juices,
and water do not have an effect in either direction, therefore
they (plus tea) become the beverages of choice for children.
Of note, when one is discussing milk with patients and their
families, the recommended intake should be within the
frame of the recommended dietary allowance (RDA) of
calcium and protein (vide infra). In adults, some studies
found all types of soda, with caffeine, without caffeine,
conventional sweet soda and diet soda, to be adequate for
use as beverages [7, 10]. However, others found lower rates
of stone recurrence in those discontinuing soda drinks,
especially when the drinks contained phosphoric acid [11].
If one wants to add an advantage to the drink used, then
those beverages containing alkali are regarded to be
superior to acidic fluids, as discussed below [6, 12, 13].
Unfortunately, it seems that, in children, the recommen-
dation for high fluid intake has only limited success. As
recently shown, even after they had been provided with the
recommendation of high fluid intake, children with calcium
stones continued to have high urine specific gravity, used as
a surrogate for urine volume, that was not different from
that of healthy, age-matched, controls [5]. This means that
further efforts should be made in finding better educational
tools and practices to instill the habit of high fluid intake.
On the other hand, all the time such a goal has not been
achieved, other preventive means should be utilized.
Nutrition
The other main non-pharmacological intervention involves
the child’s nutrition. Multiple studies have shown the
coupling between urinary sodium and calcium excretion
Table 2 Medications commonly used in the treatment of urolithiasis
Drug name Dosage (oral) Formulations Indications
Allopurinol 10 mg/kg per day. Single or divided 2–3 doses Tablet: 100 mg, 300 mg. Oral
solution: can be made from tablets
Hyperuricosuria
Captopril 0.5–1.5 mg/kg per dose. Given 2–4 times per day
(lower starting dose in infants)
Tablet: 12.5 mg, 25 mg, 50 mg. Oral
solution: 1 mg/ml may be prepared
Cystinuria
Chlorothiazide 10–20 mg/kg per day divided 1–2 doses Tablet: 250 mg, 500 mg. Oral
solution: 250 mg/5 ml
Hypercalciuria,
hyperoxaluria
Hydrochlorothiazide
(HCTZ)
1–2 mg/kg per day divided 1–2 doses Tablet: 25 mg, 50 mg. Oral solution:
50 mg/5 ml
Hypercalciuria,
hyperoxaluria
Moduretic Based on HCTZ Tablet: (HCTZ 50 mg/amiloride
5 mg)
Hypercalciuria,
hyperoxaluria
Potassium (K)
citrate
0.5 – 1.5 mEq K/kg per day. Divided 2 doses
(tablets) or 3 doses (liquid) (titrate higher if
needed)
Tablet: 5 mEq K, 10 mEq K.
Solution: 2 mEq K/ml
Hypocitraturia,
hypercalciuria,
hyperuricosuria, cystinuria
Pyridoxine (vitamin
B6)
25–200 mg/day, once daily (titrated to effect with
urine oxalate levels)
Tablet: 25 mg, 50 mg Primary hyperoxaluria
Tiopronin 15 mg/kg per day divided 3 doses Tablet: 100 mg Cystinuria
D-Penicillamine 30 mg/kg per day divided 4 doses, half at night Capsule: 125 mg, 250 mg Cystinuria
Table 1 Normal values for 24 h urine
Chemical component Value
Calcium < 4 mg (0.1 mmol)/kg per 24 hours
Sodium <3 mEq (3 mmol)/kg per 24 hours
Potassium >3 mEq (3 mmol)/kg per 24 hours
Magnesium >88 mg (44 mmol)/1.73 m
2 per 24 hours
Citrate >180 mg (94 μmol/g (8.84 mmol) creatinine
Oxalate <52 mg (593 mmol)/1.73 m
2 per 24 hours
<2 mg (23 mmol)/kg per 24 hours
Cystine <60 mg (0.5 mmol)/1.73 m
2 per 24 hours
Uric Acid <815 mg (4.9 mmol)/1.73 m
2 per 24 hours
<35 mg (0.21 mmol)/kg per 24 hours
Xanthine 30-90 μg (20–60 μmol)/24 h
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which mostly finds its way to the urine, and hypercalciuria
[14]. Moreover, in a recent study, Frassetto et al. [15]
showed that dietary sodium chloride, by means of chloride,
induces low-grade metabolic acidosis which, as discussed
below, adversely affects bone status and promotes stone
formation. For the majority of patients with calcium stones
and most other types of stones, dietary sodium adjustment
indicates a significant reduction in its intake. This is due to
the fact that, in industrialized countries, and mostly due to
food processing, the population consumes sodium in
amounts far exceeding the physiologic needs. Hence,
“sodium restriction”, in essence, should reflect changing
the habits of high sodium intake to that of optimal sodium
intake. The Food and Nutrition Board of the Institute of
Medicine, National Academy of Sciences, states that the
optimal daily intake of sodium at ages 4–8 years is 1.2 g
and, at ages 9–18 years, is 1.5 g, and the upper limit values
(namely maximal amounts not to pose health risks) are
1.9 g and 2.3 g, respectively (http://dietary-supplements.info.
nih.gov/health_Information/Dietary_Reference_Intakes.
aspx). These values are 2–3 times lower than the current
average daily intake of sodium. On the other hand, high
potassium intake has the opposite effect on urine calcium,
namely it decreases it [16]. Whether this is due to potassium
itself or to the fact that, in most cases, potassium in nature
comes in the form of alkaline salts, such as potassium citrate,
is not completely clear. In a small of group of children we
were able to show that supplementation with potassium
chloride reduced urine calcium [16]. However, it seems that
in its alkali form, potassium has a more potent effect in
decreasing urine calcium excretion [17]. The optimal daily
potassium intake, provided mostly in the form of fruit,
vegetable and dairy products, is 3.8 g at ages 4–8 years and
4.5 g at ages 9–18 years (http://dietary-supplements.info.nih.
gov/health_Information/Dietary_Reference_Intakes.aspx).
These values are 2–3 times higher than the current average
intake. Interestingly, the opposite effects of sodium and
potassium on urine calcium excretion are similar to their
effects on blood pressure, namely excess sodium (especially
in the form of NaCl) increases it, whereas high potassium
intake lowers blood pressure [18]. A simple way to assess
compliance with the above dietary recommendations related
to sodium and potassium is by measuring the urine sodium/
potassium ratio, which optimally should be below 2.5 [14].
In hypercalciuric stone formers, another important aspect
of decreasing urine calcium is by changing the diet to be
less acidic, by reducing animal-protein intake [19–21]. The
metabolism of proteins results in formation of non-volatile
acids which are buffered by bicarbonate released from
bone, through bone resorption, which, when excessive,
results in osteopenia and hypercalciuria [20, 21]. Further-
more, the acidic environment results in decreased urine
citrate [21]. Indeed, as shown by Jehle et al. [22], treatment
of adults on an acidogenic Western diet with potassium
citrate increased bone mass, decreased calciuria, and
increased citraturia. The natural source of potassium citrate
is fruit and vegetables [13].
Whereas, in the past, dietary calcium restriction or
binding with cellulose-phosphate was used to decrease
absorptive hypercalciuria, this maneuver is not practiced
any more, due to the fact that it results in increased oxalate
absorption in the gut and has the potential to affect the bone
adversely [19, 23]. Other nutrients, such as sucrose,
fructose and high-dose vitamin C, may be associated with
higher risk for kidney stone disease, whereas phytate and
magnesium may decrease it [24]. As with other nutrients, it
seems reasonable to assume that, especially in children, one
should aim at RDA intake; however, these components of
nutrition still require more research [25].
The issue of dietary oxalate restriction in patients with
calcium oxalate stone is still debatable. Whereas some
support this approach [26], others found no association
between oxalate (and spinach) with higher risk for stones
[27]. Perhaps a more clear differentiation should be made
between patients with hypercalciuria and those with
absorptive hyperoxaluria as the etiology for formation of
calcium oxalate stones, with potentially more value to
dietary oxalate restriction in the latter group (vide infra). On
the other hand, calcium supplementation, when provided
with meals, actually lowers oxalate absorption from the gut
and its amount in the urine. This may be associated, though,
with an increase in urine calcium [28].
It is strongly recommended that a nutritionist be
involved to provide the family with the specifics on how
to achieve the above nutritional goals. One should keep in
mind that nutritional habits cannot be changed overnight,
and a gradual change may be more tolerable and successful.
The role of nutrition in other disease entities will be
discussed later.
Pharmacological intervention
Calcium stones
Hypercalciuria and hypocitraturia
Treatment of patients with calcium stones due to idiopathic
hypercalciuria with potassium (K)-citrate has the dual
advantage of decreasing urine calcium and increasing urine
citrate. Furthermore, it improves the bone mineral status of
these patients [22, 29]. Naturally, K-citrate is the drug of
choice in patients with hypocitraturia. It is important though
to prevent the urine pH from becoming too alkaline thus
promoting formation of calcium phosphate stones [30]. As
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when one is assessing urine pH.
Thiazides are time-proven preparations for the treatment
of hypercalciuria. Interestingly, though, thiazides decrease
urine citrate excretion, probably by the induced hypokale-
mia [29]. It thus may be advantageous to use a combination
of thiazides plus K-sparing diuretics such as amiloride. The
effect of the latter on urine citrate has not yet been proven;
however, the combination thiazide/amiloride may have
another advantage of further lowering urine calcium
excretion compared with thiazides alone [31]. Another
option to augment the hypocalciuric effect of thiazides,
avoid hypokalemia and increase urine citrate is to use
thiazides and K-citrate in combination [17].
In some patients with calcium oxalate stones, the results of
chemical analysis of 24 h urine are normal, as is the anatomy
of the urinary system. There could be several reasons why
these patients develop stones, among them (a) abnormalities in
less common inhibitors such as magnesium (Mg), stone-
inhibitingurine proteins, orother yet unknown inhibitors; (b) it
might be that, although each individual chemical is within its
reference range, closer inspection may show that calcium and
oxalate are at their upper limit of normal, while citrate is at the
lower limit of normal; thus, their product supports stone
formation; (c) one need to keep in mind that stone formation
depends more on the concentration of the chemicals than on
their quantity;hence, lowurine output will increase theactivity
product of CaOx, even if the quantity of each individual
chemical is within the normal range. The initial treatment of
these patients should be non-pharmacological, and medica-
tions such as potassium citrate and thiazides should be addedif
the patient continues to form stones. This situation illustrates
the relative greater importance of stone analysis than that of
urine chemistry.
M o r ec o m m o n l ys e e ni na d u l t sr a t h e rt h a ni nc h i l d r e na r e
calcium stones resulting from tubular “leak” of phosphate [32].
The latter lead to mild hypophosphatemia, causing increased
production of 1,25(OH)2-vitamin D and, consequently, in-
creased calcium absorption from the gut. The diagnosis is
made by establishing the presence of low tubular threshold for
phosphate, and the treatment is with phosphate preparations.
The growing interest in recent years in the bone–stone
connection has revealed that approximately one-third of
hypercalciuric children have decreased bone mineral den-
sity [33]. Recently, Heller et al. [34] showed that, in adults
with absorptive hypercalciuria, bone mineral density was
low and histomorphology showed increased bone resorp-
tion. Treatment of these patients with alendronate, an oral
bisphosphonate preparation, decreased urine N-telopeptides,
a marker of bone resorption, and calciuria. Not less im-
portantly, patients reverted from a negative calcium balance
to a positive one. A recent preliminary report showed similar
beneficial effects of alendronate on bone and urine calcium
excretion in children with osteopenia and calcium stone
disease [35]. Further studies are needed with regard to the
potential use of bisphosphonates in cases of hypercalciuria
due to excessive bone resorption.
Hyperoxaluria
1. Primary hyperoxaluria
The traditional treatment of primary oxaluria includes
high fluid intake, thiazide diuretics, magnesium oxide,
citrate and pyrophosphates. However, while all decrease the
activity product of CaOx, none addresses the issue of
hyperoxaluria per se. Owing to the fact that the major load
of oxalate in these patients is due to the hepatic enzymatic
defect, there is little rationale to recommend extreme
restriction of dietary oxalate. However, it may make sense
for the patients and their families to exercise avoidance of
high oxalate foods (www.ohf.org/treatment.html).
It has been known for some time that 30–50% of patients
with type I disease lower their urine oxalate in response to
treatment with pyridoxine (vitamin B6). Only in recent
years has it become evident that it is the patient’s genotype
that dictates such response, seen only in those with the
commonest mutant allele, G630A [36]. Pyridoxine is
effective in individuals both homozygous and heterozygous
for these alleles, though the specific mechanism of the
vitamin’s action under these circumstances is yet unknown.
A novel approach to the treatment of hyperoxaluria might
be achieved with oral intestinal colonization with Oxalo-
bacter formigenes, which not only degrades intestinal
oxalate but also enhances colonic secretion of endogenous-
ly produced oxalate, resulting in decreased blood and urine
oxalate levels [36, 37]. In patients who develop chronic
renal failure and end-stage kidney disease, aggressive
dialysis, followed by liver and kidney transplantation, is
currently the best available approach.
2. Absorptive hyperoxaluria
Absorptive hyperoxaluria can be idiopathic (namely due
to yet unknown causes) or secondary to abnormalities in the
gastrointestinal (GI) system, mostly associated with fat
malabsorption. The treatment of this condition involves
correction of the basic GI tract anomaly, restricted dietary
oxalate intake, and, at times, increased calcium intake.
Assistance in consulting the patient on oxalate restriction
can be found at The Oxalosis and Hyperoxaluria Foundation
website (www.ohf.org/docs/Oxalate2004.pdf). Supplemental
calcium is given to compensate for calcium captured by the
unabsorbed fat and therefore not available to bind oxalate.
As discussed above, oral ingestion of Oxalobacter
formigenes may have the same effect as in primary
hyperoxaluria. The ingestion of lactic acid bacteria, which
degrade oxalate in vitro, resulted in mixed results. While
found to be ineffective in patients with idiopathic absorp-
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decreasing urine oxalate in patients with secondary absorp-
tive hyperoxaluria due to chronic fat malabsorption [39].
Cystinuria
Healthy individuals excrete fewer than 30 mg (0.13 mmol)
of cystine per day, whereas homozygote patients excrete
between 400 mg and 3,000 mg (1.7 and 13 mmol) day. The
goal of treatment is to keep cystine soluble at a concentra-
tion below 250 mg (1 mmol)/l. This means that a patient
who excretes 750 mg (3 mmol) cystine per day needs to
have a urine volume of 3 l in order to maintain the urinary
cystine soluble. The fluid intake should be distributed
throughout the day and night, which means that the patient
should have significant fluid intake before retiring to bed
and, ideally, also at least one additional intake during
sleeping hours. In reality, some patients may not be able to
achieve such a demanding goal. As cystine solubility
increases dramatically in alkaline urine, urine pH should
be kept between 7.0 and 7.5. Besides beverages and food
containing alkali, the optimal agents to alkalinize the urine
are potassium citrate and potassium bicarbonate. One may
also consider the use of acetazolamide; however, the use of
carbonic anhydrase inhibitors always carries the risk of too
alkaline urine associated with hypocitraturia, which may
result in formation of calcium phosphate stones. Urinary
excretion of cystine correlates with dietary sodium intake;
thus, a diet low in sodium is recommended, as well as
avoidance of sodium-based alkaline preparations.
In some patients the aforementioned intervention may
suffice to prevent the formation of new stones, but, in many
others, additional, specific, therapy is required [13]. Both,
D-penicillamine and tiopronin are sulfhydryl compounds
which cleave cystine into two cysteine-disulfide moieties
that are 50-times more soluble than cystine. Although the
treatment with D-penicillamine is effective, it carries a high in-
cidence of serious side effects. If needed to be used long-term,
it should be supplemented with pyridoxine (vitamin B6),
25–50 mg/day, because of the anti-pyridoxine effect of the
medication. The tendency nowadays is to use first tiopronin,
which seems to have a lower incidence of side effects.
Captopril, which is a sulfhydryl agent, has been used with
mixed results in cystinuria. The recommended dose in adults is
75–150 mg per day. Because of its potential hypotensive
effect, some recommend trying it after all other means have
been unsuccessful.
Infection-related urolithiasis
Such stones have become less common but are still seen at
times, especially in cases of underlying anatomic predis-
positions. Infection stones are mostly composed of magne-
sium ammonium phosphate (MgNH4PO4-6H2O), also
known as struvite, and carbonate apatite (Ca10[PO4]6CO3).
Struvite stones can develop very rapidly and, at times, form
a cast in the pelvocaliceal system, known as “staghorn
calculus”. The stones are formed in the presence of bacteria
such as Proteus spp., Staphylococcus aureus, Klebsiella
spp. and others which produce urease, causing the
breakdown of urea to ammonium and bicarbonate. The
latter results in alkaline urine which promotes the formation
of these stones. One of the essential management strategies
in infection-related stone is to sterilize the urinary tract.
Often, this is possible only after the infected stone has been
removed. Prevention of recurrence of such stones requires
correction of the underlying anatomic abnormality and
protection from infection. In addition, urine acidification
with acid-phosphate preparation may keep the milieu in the
kidney unfavorable for formation of such stones. Finally,
acetohydroxamic acid, a urease inhibitor, has been success-
fully used in adults, but, due to its potential serious side
effects, has not been used in children [40].
Uric acid stones
The formation of uric acid stones is due to either high rates
of urinary urate excretion or persistently low urine pH, or a
combination of the two. The first line of treatment is urine
alkalinization, optimally by potassium citrate. In case there
is a need to lower urate excretion, dietary purine restriction
is indicated (www.dietaryfiberfood.com/purine-food.php),
and, if needed, allopurinol can be added. If, in spite of
good biochemical control and optimal urine pH, the patient
continues to generate stones, urine xanthine level should be
checked for a possible etiology, as the level may rise
significantly, secondary to the treatment with allopurinol
[14]. One should keep in mind the existence of stones made
of both uric acid and calcium. In such cases, potassium
citrate would be the first line of treatment, while thiazides
and allopurinol can be used if indicated.
2,8-Dihydroxyadeninuria
This autosomal recessive disorder is caused by a deficiency
in adenine phosphoribosyl transferase, leading to excessive
formation of 2,8-dihydroxyadenine. The stones are very
similar to uric acid stones, and specialized analysis of
chemical stones is required to identify them. A strong clue
to this diagnosis are normal serum and urine concentrations
of uric acid (however, such conditions can also occur in
uric acid lithiasis caused by chronically acidic urine). These
stones are amenable to preventive treatment with allopuri-
nol and a low purine diet; however, in contrast to uric acid
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urine [13].
Other etiologies of stone disease in childhood
In some patients the development of stones is secondary to
the presence of another condition or disease causing urinary
biochemical abnormalities which promote the development
of stones [41]. For instance, immobilization, hyperparathy-
roidism, and sarcoidosis frequently cause hypercalciuria;
distal renal tubular acidosis (dRTA) hypercalciuria and
hypocitraturia; and myeloproliferative disorder hyperurico-
suria. Additionally, stones can be caused iatrogenically.
Loop diuretics, corticosteroids, and excess vitamin D cause
hypercalciuria; ketogenic diet hypocitraturia and hyper-
uricosuria; and parenteral nutrition in premature infants
hyperoxaluria. In other instances it is the medication itself,
or its metabolites, which precipitate and form stones, as in
the case of indinavir, ceftriaxone, felbamate and others. A
complete list of the conditions, diseases, and medications
associated with stone formation is beyond the scope of this
review, and more details can be found elsewhere [13, 41].
The common denominator of all these etiologies is that
identification and successful treatment of the basic disorder
(i.e. hyperparathyroidism, dRTA) or discontinuation of the
offending medication will protect the patient from devel-
oping new stones.
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Questions
(Answers appear after the reference list)
1. The minimum urine flow (in milliliters per kilogram
per hour) which protects from calcium oxalate super-
saturation is
a. >0.5
b. >0.75
c. >1.0
d. >1.5
2. The recommended maximum daily sodium intake
between the ages 9 years and 18 years is (in milligrams
per day)
a. 2,000
b. 2,300
c. 2,800
d. 3,000
3. The recommended daily intake of potassium between
the ages 9 years and 18 years is (in milligrams per day)
a. 2,900
b. 3,500
c. 3,900
d. 4,500
4. In treating cystinuria the goal is bringing urine cystine
concentration below (in milligrams per liter)
a. 250
b. 350
c. 500
d. 750
5. Dietary NaCl
a. decreases the patient’s acidic milieu
b. increases urine citrate
c. increases the patient’s acidic milieu
d. has no effect on acid–base status
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